Abstract
▴ Desvenlafaxine extended release (ER) is a once-daily selective serotonin-noradrenaline (norepinephrine) reuptake inhibitor approved in the US for the treatment of major depressive disorder in adult patients. ▴ In two of three well designed, 8-week clinical trials, desvenlafaxine ER 50 mg/day (the recommended dosage) significantly improved depression at study end, as assessed by the 17-item Hamilton Rating Scale for Depression (primary endpoint), compared with placebo. ▴ A significant difference between desvenlafaxine ER 50 mg/day and placebo treatment groups was achieved in some, but not all, secondary measures of depression or anxiety in two of three trials, including the Clinical Global Impression-Improvement and -Severity scales, the Montgomery-Asberg Depression Rating Scale and the Covi Anxiety Scale. ▴ In two of three trials, patients receiving desvenlafaxine ER 50 mg/day for 8 weeks experienced greater improvements in health-related quality of life (as assessed by the Sheehan Disability Scale and the WHO 5-item Well-Being Index) than those receiving placebo. ▴ Desvenlafaxine ER 50 mg/day was generally well tolerated by patients in 8-week trials. Most cases of nausea, the most common adverse event, were of mild to moderate severity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
